JHEP Reports

Article	Citations
Increased carbohydrate deficient transferrin: Whisky or candy?	181
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	163
Copyright and information	125
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	124
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	117
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	93
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	74
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	73
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	73
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	63
Copyright and information	60
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	59
A small animal model of chronic hepatitis E infection using immunocompromised rats	59
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	57
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	56
Emerging roles of circular RNAs in liver cancer	54
MELD 3.i: A Bayesian Updating to the Model for End-Stage Liver Disease	53
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	50
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	49
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	48
Epigenetics of alcohol-related liver diseases	47
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	46
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”	43
Predicting liver ablation volumes with real-time MRI thermometry	42
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	42

Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	41
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	41
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	41
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	40
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	40
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	40
Time for a globally unified chronic HBV terminology?	40
Editorial Board page	36
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	35
Copyright and information	35
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	34
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	34
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	34
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	33
Predicting the need for early TIPS in patients with cirrhosis and ascites: more art than science.	33
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	33
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	32
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”	32
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	32
RAC1 as a Novel Therapeutic Target for Acute Liver Failure.	31
Deep learning can predict cardiovascular events from liver imaging	31
A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium	31
Understanding virologic heterogeneity in chronic hepatitis B treatment	31
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	30
Contents	30
Editorial Board page	30
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	30
Editorial Board page	30
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study	29
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	29
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	28
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	28
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	28
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	27
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	27
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	26
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	26
Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	26
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	26
Dual-tracer PET/CT in the management of hepatocellular carcinoma	26
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	25
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	25
Application of a deep learning algorithm for the diagnosis of HCC	25
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial	25
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	25
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	25
Editorial Board page	24
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	24
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	24
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	24

Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	23
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	23
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	23
Non-invasive biomarkers of Fontan-associated liver disease	23
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	23
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	23
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	22
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology	22
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis	22
Anatomical resection is associated with reduced early recurrences in HCC: A machine learning analysis	22
Regulatory T cell therapy in autoimmune liver disease and transplantation	22
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	22
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	21
Editorial Board page	21
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	21
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	21
Does ammonia really disrupt brain oxygen homeostasis?	21
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies	20
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	20
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	20
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	20
Guideline-Enhanced Large Language Models Outperforms Physician-Test Takers on EASL Campus Quizzes Multiple Choice Questions	20
ADIPOSE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY PROTECTS AGAINST HEPATIC STEATOSIS BY UPREGULATING PPARα ACTIVITY	20
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	20
Corrigendum to ‘A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation’ [JHEP Reports 6	20
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	20
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	19
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	19
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	19
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis	19
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors	19
Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum	19
Resolvin D1-mediated cellular crosstalk protects against MASH	19
The role of cGAS-STING signalling in liver diseases	19
Copyright and information	18
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	18
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	18
Acknowledging our reviewers	18
Evolving epidemiology of HCC in Spain	18
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	18
Good long-term outcomes of primary sclerosing cholangitis in childhood	18
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	18
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	18
Innovative approaches to the management of ascites in cirrhosis	17
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	17
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	17
Thyroid dysfunction in MASLD: Results of a nationwide study	17
Copyright and information	17
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	17
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	17
High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment	17
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison	17
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	17
Estimating the clinical prevalence of Wilson’s disease in the UK	17
Contents	16
Editorial Board page	16
Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infection	16
Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development	16
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	16
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	16
Contents	16
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	16
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	16
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	16
Editorial Board page	16
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	16
Reply to: “Statins in MASLD: Challenges and future directions”	16
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	15
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	15
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	15
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	15
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	15
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	15
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	15
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	15
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	15
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	15
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	15
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	15
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	15

Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	14
Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease	14
Transcriptomic landscapes of effective and failed liver regeneration in humans	14
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	14
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	14
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	14
Contents	14
Editorial Board page	14
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	14
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	13
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?	13
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	13
Kinase Suppressor of Ras 1 (KSR1) Promotes Liver Carcinogenesis via Activation of the RAS/RAF/MEK/ERK Signaling Pathway	13
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	13
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	13
SBRT for bridging and downstaging HCC before transplant	13
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	13
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	13
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	13
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	13
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study	13
NTCP ubiquitination enables Hepatitis B Virus (HBV) infection	12
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	12
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	12
Editorial Board page	12
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	12
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	12
Editorial Board page	12
Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality	12
New targets for NAFLD	12
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	12
Contents	12
Contents	11
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	11
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	11
GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis	11
Contents	11
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	11
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	11
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	11
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	11
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study	11
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	11
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	11
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	11
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	11
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	11
Drug-induced liver injury in children: A nationwide cohort study from China	11
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	11
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	11
Risk of portal hypertensive complications preventable by TIPS in patients with ascites	11
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	11
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	11
Contents	10
Copyright and information	10
Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure	10
Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis	10
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	10
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	10
Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans	10
Copyright and information	10
Editorial Board page	10
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	10
AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection	10
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis	10
Copyright and information	10
Contents	10
Daytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality	10
Implementing a new HCV model of care for people who use drugs	10
Use of albumin infusion for cirrhosis-related complications: An international position statement	10
Hepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease aetiologies	9
Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation	9
Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial	9
Copyright and information	9
Stiffness-activated Hepatic Stellate Cells boost HCC Migration via TGM2/ITGB1-mediated Matrix Remodeling and Mitochondrial Transfer	9
Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response	9
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	9
A comment on “Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes”	9
Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses	9
24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ	9
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab	9
Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids	9
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	9
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease	9
LSECtin attenuates hepatic Th17 expansion in a murine model of cirrhosis and signals through the LAG-3 receptor	9
An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma✰	9
Reply to: “Comment on opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis”	9
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis	9
Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection	9
Macrophage-derived IL-15 imprints peritoneal TRM-like CD8 T cells in cirrhosis and spontaneous bacterial peritonitis	9
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	9
Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis	9
C/EBPβ–VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD	9
What We Missed Then, AI Sees Now: Revisiting Legacy Large EV Data to Reveal Synergistic Biomarkers for Liver Cancer Screening	9
Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy	9